{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T03:58:04Z","timestamp":1790827084775,"version":"4.1.0"},"reference-count":13,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Open Science"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.euros.2026.02.003","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T12:33:05Z","timestamp":1771849985000},"page":"71-74","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Circulating Plasma and Urine Tumor DNA in Non\u2013muscle-invasive Bladder Cancer: A Promising Biomarker to Guide Therapeutic Intensification"],"prefix":"10.1016","volume":"92","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-5263-1398","authenticated-orcid":false,"given":"Pierre-Etienne","family":"Gabriel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gautier","family":"Marcq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alec","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Sfakianos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evanguelos","family":"Xylinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euros.2026.02.003_b0005","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1038\/s41591-025-03738-z","article-title":"Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial","volume":"31","author":"Shore","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.euros.2026.02.003_b0010","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1016\/S0140-6736(25)01897-5","article-title":"Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial","volume":"406","author":"De Santis","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.euros.2026.02.003_b0015","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.annonc.2025.09.017","article-title":"ALBAN (GETUG-AFU 37): a phase III, randomized, open-label international trial of intravenous atezolizumab and intravesical bacillus Calmette-Gu\u00e9rin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle-invasive bladder cancer (NMIBC)","volume":"37","author":"Roupret","year":"2026","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euros.2026.02.003_b0020","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/j.euo.2025.06.003","article-title":"The evolving landscape of systemic immunotherapy for bacillus Calmette-Gu\u00e9rin\u2013na\u00efve high-risk non\u2013muscle-invasive bladder cancer: at the edge of a tsunami?","volume":"8","author":"Gabriel","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euros.2026.02.003_b0025","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa2511885","article-title":"ctDNA-guided adjuvant atezolizumab in muscle-invasive bladder cancer","volume":"393","author":"Powles","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euros.2026.02.003_b0030","doi-asserted-by":"crossref","unstructured":"Pandolfo SD, Bukavina L, Autorino R. Re: ctDNA-guided adjuvant atezolizumab in muscle-invasive bladder cancer. Eur Urol. In press. https:\/\/doi.org\/10.1016\/j.eururo.2025.12.006.","DOI":"10.1016\/j.eururo.2025.12.006"},{"key":"10.1016\/j.euros.2026.02.003_b0035","article-title":"Circulating tumor DNA analyses predict disease recurrence in non-muscle-invasive bladder cancer","volume":"11","author":"Zhang","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.euros.2026.02.003_b0040","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.euo.2025.05.019","article-title":"Real-world experience with a commercial circulating tumor DNA assay in non\u2013muscle-invasive bladder cancer","volume":"8","author":"Wang","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euros.2026.02.003_b0045","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2016.01.007","article-title":"Genomic alterations in liquid biopsies from patients with bladder cancer","volume":"70","author":"Birkenkamp-Demtr\u00f6der","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2026.02.003_b0050","doi-asserted-by":"crossref","unstructured":"BinHumaid FS, Goel A, Gordon NS, et al. Circulating tumour DNA positivity predicts shorter survival for patients with high-grade pT1 urothelial bladder carcinoma. Eur Urol. In press. https:\/\/doi.org\/10.1016\/j.eururo.2025.11.007.","DOI":"10.1016\/j.eururo.2025.11.007"},{"key":"10.1016\/j.euros.2026.02.003_b0055","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.eururo.2025.03.023","article-title":"Urine tumor DNA to stratify the risk of recurrence in patients treated with atezolizumab for bacillus Calmette-Gu\u00e9rin\u2013unresponsive non\u2013muscle-invasive bladder cancer","volume":"88","author":"St-Laurent","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2026.02.003_b0060","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.eururo.2016.12.016","article-title":"Liquid biopsy analysis of FGFR3 and PIK3CA hotspot mutations for disease surveillance in bladder cancer","volume":"71","author":"Christensen","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2026.02.003_b0065","doi-asserted-by":"crossref","first-page":"e1008","DOI":"10.1002\/ctm2.1008","article-title":"Non-invasive diagnosis and surveillance of bladder cancer with driver and passenger DNA methylation in a prospective cohort study","volume":"12","author":"Xiao","year":"2022","journal-title":"Clin Transl Med"}],"container-title":["European Urology Open Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666168326000352?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666168326000352?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T03:26:49Z","timestamp":1790825209000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666168326000352"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":13,"alternative-id":["S2666168326000352"],"URL":"https:\/\/doi.org\/10.1016\/j.euros.2026.02.003","relation":{},"ISSN":["2666-1683"],"issn-type":[{"value":"2666-1683","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Circulating Plasma and Urine Tumor DNA in Non\u2013muscle-invasive Bladder Cancer: A Promising Biomarker to Guide Therapeutic Intensification","name":"articletitle","label":"Article Title"},{"value":"European Urology Open Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euros.2026.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}